Postdoctoral Fellows Recruitment of Guangzhou Women and Children's Medical Center

Guangzhou Women and Children's Medical Center

Guangzhou, China

Guangzhou Women and Children’s Medical Center (hereinafter referred to as GWCMC) is one of the most concentrated medical institutions for pediatrics, obstetrics and gynecology in South China. It has a number of national and provincial clinical specialties and key laboratories. It is the affiliated hospital of Sun Yat-sen University (not directly affiliated), Guangzhou Medical University (not directly affiliated), the teaching practice base of Southern Medical University, and the graduate training base of Jinan University. From 2016 to 2019, it has received grants for nearly 30 projects from NSFC for four consecutive years. A national post-doctoral working station has been established, with more than 70 post doctors currently working in it.

GWCMC has abundant clinical specialties including Pediatric respiratory department, Pediatric gastroenterology department, Pediatric infection department, Pediatric nephrology department, Pediatric rheumatism and immunity department, Pediatric genetics and endocrinology department, Pediatric hematology and oncology department, Pediatric neurology department, Pediatric rehabilitation department, neonatal department (including NICU), PICU, Pediatric emergency department, Gynecology department , Obstetrics department, Prenatal diagnosis department, Clinical Laboratory, Clinical pathology department, Reproductive medicine center, Radiology department, Ultrasonography department, Intervention and angioma department, etc.

GWCMC has multiple independent laboratories, research centers and public platforms, such as Clinical data center, Clinical medical research center, Born in Guangzhou Cohort Study, and Clinical biological resource bank. It has introduced more than 10 principal investigators (PI) from around the world. Research fields include: surgical hepatobiliary diseases , neurodevelopment and behavioral genetics, endocrine and metabolic diseases, systems biology, uterine vascular biology, acquired cardiovascular system diseases, infection and immunology, stem cell and cardiovascular repair research, bacteriology and clinical immunology. Please see below the detailed introduction of each PI .

In order to further develop our scientific research capacity, we are sincerely recruiting more postdoctoral fellows.

(1). Age below 35 years old, doctoral degree obtained for no more than 3 years (in principle); those who have published SCI papers are preferred;

(2). Background in clinical medicine, basic medicine, biology, biomedical engineering, and bioinformatics, including genetics, developmental science, immunology, stem cells, tumors and other related fields;

(3). Able to independently undertake or assist in completing related projects;

(4). Assist in making project plans and writing research papers, participate in research fund applications;

(5). Fluent in English listening, speaking, reading and writing;

(6). Must be engaged in full-time post-doctoral research work, part-time one is forbidden according to regulation.

(1) Based on applicant’s scientific research ability, the annual salary ranges from 260,000 to 450,000 (before tax), including a housing allowance of 3,000 yuan per month.

(2) Each postdoctoral fellow is entitled to 500,000 research funds.

(3) Postdoctoral fellows in clinical specialties will be additionally granted clinical research awards.

(4) All postdoctoral fellows are included in the scientific research reward system of GWCMC.

(5) After completing work in the station, those who perform well will be chosen to stay in GWCMC.

Please send your resume via e-mail. The subject of the e-mail should be “name + job position”.
Email address:
Tele: 020-38076501.

Recruitment Process:
Submit resume → Resume screening → Interview → Medical examination → Admission → Enter postdoctoral station

Introduction of part of PI (including only basic scientific research PI, clinical PI is the director of each clinical specialty, if you need to know more information, you can check the specialty introduction on the official website of our hospital) :

1. Huimin Xia

Huimin Xia,professor of Pediatric Surgery, chief physician and doctoral supervisor, honored as the Special Allowance Expert of Chinese State Council and Leading Medical Talent in Guangdong Province, has been engaged in clinical and scientific research in pediatrics for over 30 years.

Professional affiliations of Prof. Xia include: chairman-elect of Pediatric Surgery Society, Chinese Medical Association; chairman of Pediatric Surgery Society, Guangdong Medical Association; vice chairman of Guangdong Provincial Hospital Association, as well as deputy editor of Chinese journal of Pediatric Surgery. As the corresponding author, he has published more than 43 Science Citation Index (SCI) research papers, two of which were published in Nature Reviews Materials (IF74.449) and Nature Medicine (IF30.641). With one of his articles in Molecular Psychiatry (IF11.973), he has arisen attention to the induction and differentiation of hiPS intestinal neurons and the treatment of megacolon. He also worked as the chief or deputy editor of 8 academic works in total, and obtained 4 Chinese National Invention Patents. In recent years, he has served as the Program Director of 5 national level projects supported by the National Natural Science Foundation and National Key Clinical Specialties Foundation in China, with the overall grants exceeding 20 million RMB yuan. Among his many accomplishments, he was awarded the Soong Ching-ling Pediatric Medicine Award, third prize of Science and Technology Award in Guangdong Province, the second prize of Science and Technology Award in Guangzhou.

Guangdong Provincial Key Laboratory of Research in Structural Birth Defect Disease:Established in 2019 upon the approval from The Department of Science and Technology in Guangdong Province, the lab focuses on areas of common structural birth defects with poor prognosis, including congenital megacolon, biliary atresia and childhood malignant tumors, and we are working to estimate the effects of genetic and environmental factors on the structural birth defects above mentioned, and to further clarify the underlying etiology and mechanisms, hoping to get some new insights for early diagnose and management.

Since we started the lab preparation in 2014, the team has grown into a research group with 10 High-level Overseas Returnees, 10 PhD researchers, 12 technicians, and 6 graduate students. The lab conducts researches into genetics, immunology, cell biology and 3-D printing, and during the past three years, we have achieved in carrying out 14 projects supported by the National Natural Science Foundation of China, and publishing over 50 Science Citation Index (SCI) research papers. In 2020, adequate job positions are available for post-doctoral researchers, assistant researchers and implementation technicians in research fields including Genetics, Developmental Science, Stem Cell, Oncology, Immunology to 3-D printing.

2. Ya-Ping Tang

Professor Tang Ya-ping joined Guangzhou Women and Children’s Medical Center as a high-level foreign expert of Guangzhou in 2015. He is currently the executive director of Institute of Pediatrics, and PI of Laboratory of Neurodevelopmental and Behavioral Genetics. He received his doctor’s degree in medicine from the National Nagoya University of Japan, then successively served in Princeton University (Postdoctoral), University of Chicago (Assistant Professor), LSUHSC Medical Center (Associate Professor), and Veterans Affairs Bureau (Investigator). His lab mainly focuses on three research filed: the neurobiological basis and clinical diagnosis and treatment of Autism, the pathogenesis and gene therapy of rare genetic diseases, and the clinical transformation and application of modified stem cells. He has published more than 50 SCI papers in the world’s top journals , such as Nature, Science, Cell, PNAS, Neuron, NAT Neurosci, NAT Med, with a total impact factor of nearly 400 and a total number of citations of nearly 8000. One of his studies was selected as the “Top Ten Medical Breakthroughs of the Year” by Times. He has won the Young Scholar Award of the American Alzheimer’s Foundation, the Young Scholar Award of the American Neuropsychiatry Foundation, and the Research Award of Wang Kuancheng Education Foundation of the Chinese Academy of Sciences. He served as editorial board member of PLoS One and Chinese Journal of Modern Neurology, reviewer of Science, NAT Neurosci, Neuron, PNAS, Mol Psychiatry, J Neurosci and other journals. He also served as the reviewer of Alzheimer’s Disease Foundation (US), NARSAD (US), Philip Morris External Research Foundation (US), BBSRC (UK), Welcome Trust (UK) and NIH (US). He has obtained more than 20 scientific research funds in the United States and China, with a total amount of nearly 100 million yuan. At present, the laboratory’s active research projects include 2 NSFC general projects, 1 Research and Development Plan Project in key areas of Department of Science and Technology of Guangdong (40 million), 1 Major International Joint Research Project, and 1 Major Special Project of Science and Technology Innovation Commission of Guangzhou.

3. Tang Wai Ho

Tang Wai Ho is currently the associate director of Institute of Pediatrics at Guangzhou Women and Children’s Medical Centre. He obtained his PhD from the faculty of medicine at the University of Hong Kong, and pursed his Postdoctoral training at Yale University. His research focuses on the pathogenesis of cardiovascular disease and the molecular mechanism underlying vascular remodelling, and his studies have been published in the internationally recognised SCI journals, including Circulation (IF: 18.881), J Clin Invest (IF: 13.251) and EMBO Mol Med (IF: 10.293). After returning to China in 2015, Prof Tang’s lab has been extensively funded by the National Natural Science Foundation of China and Guangdong Province, and he also received the recognition from Guangdong Distinguished Young Scholar, Guangdong High-level Talent Program, and Guangzhou High-level Talent Program etc. Since 2016, Prof Tang’s lab has published five SCI research articles in our institute, and among which, the most representative work “Platelet-derived miR-223 promotes a phenotypic switch in arterial injury repair” published in J Clin Invest in 2019 is the first SCI research article IF>10 published by our institute. The study demonstrates that platelets deliver miRNAs to vascular smooth muscle cells, and participate in the pathogenesis of diabetic vascular disease by regulating the phenotypic transition of vascular smooth muscle cells. This novel cell-cell communication suggests that platelets are potentially developed for the specific targeted drug carriers in the treatment of diabetes-related vascular diseases.

4. Hu Hao

Prof. Dr. Cougar Hao Hu, principle investigator in Guangzhou Institute of Pediatrics, Guangzhou Women and Children’s Medical Center since August, 2015. He got a Ph.D in 2005 from Shanghai Institute of Biochemistry, Chinese Academy of Sciences, and worked as a research assistant in National Center for Gene Research in 2006; he finished a round of postdoc training during 2007-2008 in Shanghai Institute of Computational Biology, Chinese Academy of Sciences. He worked in Max-Planck Institute for Molecular Genetics, Germany, during 2009-2015, and was promoted as a group leader since 2013. Hu’s research interests focus on the etiology of neurodevelopmental diseases, including intellectual disability and cerebral palsy, which are among the major causes for children referred to the neuropediatric departments. He has screened cohorts and identified more than 200 disease-related defective genes, and through network analyses and functional assays, he established a couple of critical modules involved in the early development of human brain.

In his lab, they leverage deep sequencing technology and a diversity of molecular and cellular approaches, combined with model organisms and organoids. His publications with major authorships since 2011 include Nature (1), Molecular Psychiatry (2), American Journal of Human Genetics (2), PLoS Genetics (1), Human Mutation (1), and European Journal of Human Genetics (1). His current research grants are from National Natural Science Foundation of China (2) and Guangzhou Science Technology and Innovation Commission (1), summing up to 6 million RMB.

5. Gendie Lash

Gendie Lash currently heads the Laboratory of Uterine Vascular Biology. She obtained her PhD in Biochemistry from the University of Otago, Dunedin, New Zealand and worked as a post-doctoral fellow and lecturer at University of Nottingham (UK), Queen’s University (Canada) and Newcastle University (UK) prior to joining GIP in 2015. Since joining GIP she has published 13 papers from her group or in collaboration with clinical researchers within GWCMC, as well as several others with international collaborators. She is currently the Editor of Trophoblast Research, serving on the editorial board of several other journals and is frequently invited to present her research at National and International conferences. Her laboratory is well funded by the National Science Foundation of China and Guangzhou Municipal Science and Technology Fund. In addition she has been recognized as Guangzhou key medical talent. Her research group is made up of a dynamic group of scientist including senior scientist, post-doctoral fellows, technicians and master’s students.

Research in the Uterine Vascular Biology Laboratory focuses on 4 main themes.

(1). Regulators of trophoblast invasion
Invasion of the maternal decidua and inner third of myometrium by extravillous trophoblast cells and the subsequent remodeling of the uterine spiral arteries is one of the key events in early pregnancy; failures in these processes being associated with major complications of pregnancy. Our research aims to identify some of the key regulatory mechanisms in these processes with the ultimate aim to develop early interventions for prevention of these pregnancy complications.

(2). Regulators of VSMC (de)differentiation
Vascular smooth muscle cells can switch from a synthetic to contractile phenotype and vice versa depending on the microenvironment. The switch from contractive to synthetic is a key feature of spiral artery remodeling and we have identified Ang2 and vitamin D as one of the key mediators of this process. Our research aims to understand the molecular basis of this phenotypic switching and how it can be utilized therapeutically.

(3). Regulators of endometrium maturation in health and disease (recurrent miscarriage, heavy menstrual bleeding, endometriosis)
Aberrant endometrial maturation is a feature of recurrent miscarriage (advanced) and heavy menstrual bleeding (halted) associated with TGF-β1 signalling. Current research is focused on understanding the complete molecular basis of this to develop therapeutics for these important gynecology conditions.

(4). Regulators of tumor angiogenesis, metastasis and progression (breast, endometrial and ovarian)
Poor prognosis for many types of tumors is associated with tumor angiogenesis and cancer cell metastasis. Many of the same pathways being investigated in the tightly regulated process of trophoblast invasion/spiral artery remodeling are also relevant to tumor angiogenesis and metastasis where they occur in an uncontrolled manner. Therefore we can learn about both systems by drawing parallels between them.

6. Zhang Yuxia

Yuxia obtained her PhD from the Chinese Academy of Sciences in 2007, followed by 2 years post-doctoral training in the Christopher Rudd Laboratory at the University of Cambridge (UK) (2007-2008). She joined the Leonard Harrison Lab at Walter and Eliza Hall Institute of Medical Research (WEHI) in February 2009 and was promoted to Senior Research Officer in 2014. She was appointed Lab Head April 2016 at Guangzhou Women and Children’s Medical center (GWCMC), Guangzhou Medical University. She bridges mouse and human immunology studies with cutting-edge epigenetic, metabolomic and cell signaling methodologies, and has identified novel biomarkers and pathogenic mechanisms in autoimmune and allergic diseases, and therapeutic targets and agents.

Her lab currently focuses on immune pathogenesis and novel treatment strategies for inflammatory bowel diseases (IBD) and biliary atresia (BA). They employ cutting-edge techniques including single cell RNA sequencing, whole genome-wide association study, whole exosome sequencing, comparative immune profiling, animal experiments and clinical trials to identify how risk and disease causal genes regulate intestinal and hepatic immune and non-immune cell development and function.

7. DuanJinzhu

Dr. Jinzhu Duan obtained his Ph.D. in Microbiology and Molecular Immunology, Institute of Microbiology of Chinese Academy of Sciences. He worked as a Postdoctoral fellow at the University of North Carolina at Chapel Hill, and worked as an Assistant Researcher at the Department of Cardiology in the University of California, Los Angeles, USA. He was appointed as the principle investigator (PI) in Cardiac Injury Repair and Regeneration Laboratory of Guangzhou Women and Children’s Medical Center in 2016. He was awarded as the key talent in high-level health medicine and a second-tier reserve talent in the “Lingnan Yingjie Project” in Guangzhou. He is now a member of the 1st Committee of the Epidemic Pharmacology Professional Committee of the Chinese Pharmacological Society in 2018 and the 1st Committee of the Stem Cell and Tissue Engineering of the Chinese Society of Bioengineering in 2019. He is also a member of the Basic Research Group of the 10th Committee of the Cardiovascular Diseases of Guangdong Medical Association in 2018.

His lab focuses on the study of cardiac injury repair and regeneration. The current research includes the regulation mechanism of cell differentiation / reprogramming, the interrelation of immunity and tissue regeneration, and the epigenetic modification of cardiomyocytes. In addition, extensive cooperation with the clinic has been carried out to study the pathogenesis of severe congenital heart disease and the stem cell therapy. His article has been published in Nature, EMBO J, PLoS One, and FASEB J., etc., and has been reported by the media. The Nature article has been recommended in F1000 Prime as being of special significance in its field. His research work has been also awarded as Louis N. and Arnold M Katz Basic Medical Research Award from the American Heart Association, and he himself received Jim Eason Cardiovascular Discovery Fund from UCLA and Joseph S. Pagano. Excellent Postdoctoral Award from UNC at Chapel Hill.

8. Andrey Zavialov

Dr. Zaviyalov started to work at the Institute of Pediatrics of Guangzhou Women and Children’s Medical Center in May 2017 as PI of Clinical Immunology Laboratory. Majoring in molecular biology, he graduated from the Department of Cell and Molecular Biology, University of Uppsala, Sweden. He has conducted post-doctoral research at Uppsala University (Sweden), and has subsequently worked as a research scientist in immunology at the Singapore Immunology Network Corporation, and as an assistant professor of medical immunology research at the University of Hawaii at Manoa.

From 2011 to early 2016, he has served as the PI of the Immunology Laboratory of the Biotechnology Center at the Institute of Turku University in Finland. He found Adenosine deaminase (ADA2) in immunoglobulin preparations while studying in Russia and has been working on related research ever since. He has been funded by a number of national research funds and has carried out research in Russia, France, Singapore, the United States and other places and cooperated with Spanish and Swedish experts. During research, he has been granted a large number of scientific research projects and published 31 SCI papers, including 6 in Cell, 2 in Nature, 3 in Molecular Cell, 1 in JAMA, 1 in New England Journal of Medicine and so on. His theories related to the regulatory mechanism of GTPase activity that terminates and translates prokaryotic translation are written in textbooks for biochemistry.

Brief description of current research:

It has been shown that adenosine plays an important role in the regulation of immune responses. Adenosine accumulates at sites of inflammation and tumor growth and binds to adenosine receptors that are expressed by immune cells in response to activation signals. However, the role of adenosine deaminases, which decrease the local concentration of adenosine, is still unclear. Moreover, it remains puzzling why humans possess two enzymes, ADA1 and ADA2, with adenosine deaminase activity. ADA1 is largely an intracellular enzyme that breaks down adenosine and reduces the concentration of the adenosine derivatives that are toxic to immune cells. It has been found that mutations in the ADA1 gene lead to a severe combined immunodeficiency that is characterized by decreased antibody production and lower numbers of T and B cells. In contrast to ADA1, ADA2 is a secreted protein expressed mainly by cells of the myeloid lineage, such as macrophages and dendritic cells. Clinical studies have shown that the levels of ADAs in biological fluids are altered in pathophysiological conditions, suggesting that ADA activity could be a convenient marker for the diagnosis of immune diseases such as tuberculosis and oral cancer. We have identified the gene encoding ADA2 and shown that it belongs to a new family of adenosine deaminase growth factors (ADGFs). The crystal structure of ADA2 reveals it to be a dimer with two chemokine-like domains that could potentially bind a putative ADA2 receptor. We found that ADA2 binds to neutrophiles, CD16+ monocytes, NK cells and B cells that do not express CD26, a receptor for ADA1. These observations suggest the existence of a new mechanism by which ADAs bind to and regulate the activity of different lymphocyte subsets. Recently, patients with mutations in the gene encoding ADA2 (DADA2 patients) were identified. These patients display multiple health problems such as early onset systemic inflammation, multiple ischemic strokes, panlymphopenia and hypogammaglobulinemia. The aim of my project is to shed light on the function of ADA2, the enzyme that is currently thought to be a drug candidate to combat solid tumors, and find its clinical applications.

9. Li Jia

Professor Li Jia received her Bachelor Degree from Peking University Health Science and PhD Degree from Imperial College School of Medicine in UK. She worked as an Associate Professor in Canada. In 2013, selected by the Sea Poly Project of Beijing Overseas Talents program, she worked as Full Professor and the Director of Pediatric Clinical Pathophysiology Laboratory in Capital Institute of Pediatrics. Since December 2018, she has started working as a Principal Investigator in Guangzhou Women and Children’s Medical Center. Her research focuses on the relationship between perioperative and long-term pathophysiology and clinical outcomes of congenital heart disease (CHD), genetic basis of CHD, and pathophysiological changes caused by altitude hypoxia.

In the past 20 years, she has conducted in-depth and systematic clinical studies on the postoperative oxygen transport balance of CHD children. Relevant findings have provided scientific basis for clinical improvements and been adopted by international peers. She has also investigated perioperative cerebral oxygen transport and brain injury and risk factors, in relation to long-term neurodevelopmental outcomes of CHD children. Another field of her research is on early postoperative nutrition and the alternations in gut microbiota.

Up to now she has published 118 peer-review papers, mostly as the first or corresponding author. Most papers have been published in internationally recognized journals of cardiac research, including cardiology journals [Circulation (IF 23.054), J Am Coll Cardiol (IF 18.639),], cardiac surgery journals [J Thorac Cardiovasc Surg (IF 5.261)], and intensive care journals [Crit Care Med (IF 6.971)]. She has also published two books (The OmniScriptum GmbH & Co. Kg. Press and The Union Medical University Press).

10. Jin Ling Tang

Jin Ling TANG is currently the Clinical Research Director of the Guangzhou Women and Children’s Medical Center. He obtained his Master of Science degree in epidemiology in London School of Hygiene and Tropical Medicine and PhD in the University of London, and received post-doctoral training in the University of Oxford.

He is con-currently appointed the Chairman of Peking University National 211 Project Committee for Evidence-Based Medicine and heads the Hong Kong Cochrane Branch of the Cochrane Collaboration and is the Chairman of the Asia Pacific Network for Evidence-Based Medicine. He co-authored Evidence-Based Decision Making in Healthcare with Sir Muir Gray of the University of Oxford and was the co-editor of the Chinese version of the BMJ Clinical Evidence. He has been invited to lecture at more than 100 domestic and international famous universities and academic conferences, with a total research funding of more than 40 million Hong Kong dollars. His major research interests include systematic reviews and meta-analysis, evidence-based medicine and evidence-based healthcare, clinical evaluation of traditional Chinese Medicine, primary prevention of cardiovascular disease, clinical trials, evaluation of diagnosis, and epidemiology.

He published more than 150 English SCI papers, total citations over 7000, more than 35 publications in medical journals with an impact factor greater than 10, authored more than 20 chapters for domestic epidemiology, evidence-based medicine, public health and other textbooks and monographs with more than 500,000 words. He has supervised ten PhD students and over seventy MPH/MSc students.

11. Huiying Liang

Huiying Liang, PhD, Professor, Guangzhou Women and Children’s Medical Center

Professor Huiying Liang is the director of the big data laboratory of the Guangzhou Women and Children’s Medical Center and Guangdong Provincial Engineering & Technology Research Center for AI Applications in Healthcare. Professor Liang has a major interest in evidence-based healthcare, bio-informatics, and AI-application of big medical data. He is the vice chairman of the Clinical Epidemiology Group, Chinese Pediateric Medical Association. He is a member of the Standing Committee of the Technical Committee on Precision Medicine, China Maternal and Child Health Association. He is a member of the Digital Medicine and Medical Informatization Branch, Chinese Society of Biomedical Engineering. He is also the deputy chairman of the Smart Medical Branch of the Guangdong Biomedical Engineering Society.

Bachelor of Preventive Medicine, Master of Epidemiology and Health Statistics, Professor Liang obtained his PhD in Bioinformatics and pursed his Postdoctoral training in Clinical Epidemiology. He has long been engaged in scientific research on medical big data and intelligent applications, working as the PI of the “Mimu Bear” smart family. His team has formed a series of core AI related technologies in NLP and text analysis, medical image processing, cross-modal analysis reasoning, etc. Leading the team to host 3 national key R & D projects related to medical artificial intelligence, he has published more than 80 papers and applied for 8 invention patents, and 12 software copyrights. Among them, 30 SCI papers have been published as the first author, and the representative journals include 2 “Cell” and 1 “Nature Medicine”. Awarded with the Guangzhou high-level talents and Guangzhou key medical talents.

12. Xiu Qiu
Xiu Qiu, MD, PhD, Chief Consultant, Doctoral Supervisor

Director of the Department of Women’s Health Care, Director of the Division of Birth Cohort Study, Guangzhou Women and Children’s Medical Center

Academic Leader of High-level Key Clinical Specialty of Guangdong Province – Maternal and Child Health Sciences

Outstanding Young Medical Personnel of Guangdong Province

Reserve Personnel of Guangzhou “Lingnan Yingjie” Project

Leading Medical Personnel of Guangzhou High-level Health Professionals

Doctoral Supervisor of Jinan University

Doctoral Supervisor of Guangzhou Medical University

Master Supervisor of Sun Yat-sen University

External Doctoral Supervisor of the University of Oxford

External Doctoral Supervisor and Honorary Senior Research Fellow of the University of Birmingham

Overview of the main research work:

In the context of China’s rapid social and economic development, Dr Qiu took the lead in establishing the Born in Guangzhou Cohort Study (BIGCS), a large prospective cohort of the general population. Since its launch in February 2012, the BIGCS has developed into a globally well-known cohort with international first-class management levels. So far, there have been more than 43,000 families recruited in the cohort and more than 2.3 million aliquots of biospecimens stored in the biobank. An information management system has been developed with independent intellectual property rights, allowing for informationized management for the whole process and visualized management for biospecimens.

The maternal and child health research platform with the BIGCS as the core has supported over 30 major scientific research projects, with research funding of more than 30 million yuan. Dr Qiu is the Principal Investigator of 1 Natural Science Foundation of China Project, 2 Ministry of Science and Technology Key Special Sub-Projects, 2 Guangdong Science and Technology Projects, 2 Guangzhou Major Science and Technology Special Projects, and 2 International Cooperation Projects. Since 2012, she has published more than 50 peer-review papers, with 39 as the (co-)first or (co-)corresponding author in recent 5 years, and more than 40 papers in Chinese core journals. She also participated in writing the book Ambient Temperature and Health in China (Springer Press) and 11 Chinese books.

Dr. Qiu is the Deputy Director of the Youth Committee of Chinese Preventive Medicine Association Women’s Health Care Branch, Deputy Head of China Medicinal Biotechnology Association Biobanking Branch Pediatrics Group, Member of Committee for Prevention and Control of Birth Defect of Chinese Medical Association Pediatrics Society, Member of the Youth Committee of Chinese Preventive Medicine Association Child Health Care Branch, Member of the Society for Pediatric and Perinatal Epidemiologic Research (SPER), and Member of the International Childhood Cancer Cohort Consortium (I4C). She is also the ad hoc reviewer of internationally renowned journals such as The Lancet, BMJ, Microbiome, Diabetologia, Paediatric and Perinatal Epidemiology, and Science of the Total Environment.

Apply with CV and Cover Letter

Must be a .doc, .docx, or .pdf file and no larger than 1MBMust be a .doc, .docx, or .pdf file and no larger than 1MB

Postdoctoral Fellows Recruitment of Guangzhou Women and Children's Medical Center